Singular Research Issues "Buy" Rating on Nymox With New Price Target of $14.50

/ Source: GlobeNewswire

HASBROUCK HEIGHTS, N.J., Dec. 22, 2010 (GLOBE NEWSWIRE) -- Singular Research has issued a new report on Nymox Pharmaceutical Corporation (Nasdaq:NYMX) with a "Buy" rating and a 12 month target price of $14.50. The report was written by Gregory P. Garner, CFA, an equity research analyst for Singular Research. According to the report, "Announcement of marketing agreement for NX-1207 to cover Europe, Middle East, Russia, and parts of Africa. This event validates the company's compound that addresses enlarged prostate."

About Nymox: NX-1207 is a novel patented drug developed by Nymox which is currently in Phase 3 trials. The Company announced on December 16, 2010 a partnership with Recordati S.p.A. for European marketing of NX-1207. The drug has successfully completed a series of blinded controlled multi-center U.S. clinical trials where a single dose of NX-1207 has been found to produce symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs. NX-1207 is injected by a urologist in an office setting and involves little or no pain or discomfort. For more information about the NX-1207 Phase 3 clinical trials please go to or contact Nymox at BPH treatment represents a growing market with more than 100 million men worldwide being estimated to suffer from BPH symptoms. The disorder is a common affliction of older men, affecting approximately half of men over age 50 and close to 90% of men by age 80, and is associated with growth in prostate size as men age. More information about Nymox is available at , email:, or 800-936-9669. Nymox made no payments to Singular Research for the research report.

About Singular Research: Singular Research aims to be the most trusted supplier of independent research on small-cap companies. We provide Honest Advice: Our Independent analysts have no financial interest in the stocks we cover. Analysts are compensated based on the accuracy of their research calls not through trading commissions or investment banking fees. For more information visit: , or call 818-222-6915.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities

CONTACT: Nymox Pharmaceutical Corporation Roy Wolvin 1-800-93NYMOX